Tenax Therapeutics (TENX) Net Margin (2011 - 2015)

Tenax Therapeutics (TENX) posted quarterly Net Margin of 9877.81% for Q2 2015, down 736.66% on a QoQ basis from 1551.5% in Q2 2013.

Tenax Therapeutics (TENX) Net Margin (2011 - 2015) Analysis & Trends

Tenax Therapeutics has reported Net Margin for 5 years, with the latest figure at 9877.81% in Q2 2015.

Net Margin for Q2 2015 came in at 9877.81%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2016 was 12031.27% (up 1241157.0% YoY), and the FY2015 annual result was 40331.1%, changed N/A from the prior year.
Net Margin eased to 9877.81% in Q2 2015, from 1551.5% in the prior quarter.
Over five years, Net Margin peaked at 10522.58% in Q1 2011 and troughed at 11513.99% in Q3 2011.
A 4-year average of 1030.51% and a median of 302.46% in 2012 frame the typical range for Net Margin.
The largest YoY upside for Net Margin was 1283211 bps in 2012 against a maximum downside of 1538948 bps in 2012.
A 4-year view of Net Margin shows it stood at 3532.82% in 2011, then soared by 109 bps to 302.46% in 2012, then surged by 413 bps to 1551.5% in 2013, then tumbled by 737 bps to 9877.81% in 2015.
Per Business Quant data, the three most recent Net Margin figures were 9877.81% in Q2 2015, 1551.5% in Q2 2013, and 1085.02% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Tenax Therapeutics	80.73 Mn	80.73 Mn	-	-

Download Data